Search Results 2221-2230 of 26315 for stem cell
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013 Oct; 123 (10):4144-57 Epub 2013 Sept 03
Mesenchymal stem cell therapy for focal epilepsy: A systematic review of ... Stem Cell Homing: Implication for Cellular Therapy. Mayo Clin Proc Innov ...
The purpose of this study is to perform RNA sequencing on induced pluripotent stem cells (iPSC). By comparing the gene expression of motor neurons derived from ...
History of bone marrow transplant (BMT), hematopoietic stem cell transplantation (HSCT), or gene therapy or undergoes BMT, HSCT, or gene therapy at any point ...
Pierre Noel, M.D.. Internist; Hematologist. Phoenix, AZ. Areas of focus: Bone marrow transplant, Allogeneic stem cell transplant, Autologous stem cell ...
Allogeneic stem cell transplant, Autologous stem cell transplant, Multiple myeloma, Amyloidosis. Gregory J. Gores, M.D.. Internist ...
Should be stopped ≥ 2 weeks prior to leukapheresis. Allogeneic cellular therapy; Must be ≥ 3 months from allogeneic stem cell transplant at the time of ...
Brain Tumor Stem Cell Research: Alfredo Quinones-Hinojosa, M.D. · Cellular Mechanisms of Neurodegenerative Disorders: Fabienne C. Fiesel, Ph.D. Comparative ...
The therapy for this type of cancer usually is a stem cell transplant, but Tanis had no suitable matching donor. ... In CAR-T cell therapy, T cells are ...
Pierre Noel, M.D.. Internist; Hematologist. Phoenix, AZ. Areas of focus: Bone marrow transplant, Autologous stem cell transplant, Allogeneic stem cell ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.